Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor

Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor

Immune checkpoint inhibitors have shown anti-tumour activity in cancers such as melanoma, renal cell carcinoma, non-small-cell lung cancer, urothelial carcinoma, colorectal cancer, and Hodgkin’s lymphoma. Though immune checkpoint inhibitors have revolutionized the treatment and prognosis of some adv...

Full description

Bibliographic Details
Main Authors: Marta Rocha, João Correia de Sousa, Marta Salgado, António Araújo, Isabel Pedroto
Format: Article
Language:English
Published: Karger Publishers 2018-12-01
Series:GE: Portuguese Journal of Gastroenterology
Subjects:
Immune checkpoint inhibitor
Immune-related adverse event
Colitis
Diarrhoea
Online Access:https://www.karger.com/Article/FullText/494569

Internet

https://www.karger.com/Article/FullText/494569

Similar Items